3D Bio Holdings

3DBio Therapeutics is a clinical-stage regenerative medicine company focused on creating living tissue implants using proprietary 3D bioprinting technology. The company's platform, GMPrint, integrates specialized bio-inks, a sterile bioprinter, and advanced imaging to produce patient-specific, living anatomical structures. In 2022, the company achieved a significant milestone by successfully transplanting a 3D-bioprinted living ear reconstructive implant into a patient with microtia. 3DBio's pipeline extends beyond ear reconstruction to include applications in nasal reconstruction, hernia repair, and spinal disc replacement.